Overview

A Phase II Study of 2 Doses of ZD6474 (Vandetanib) in Combination With FOLFOX vs FOLFOX Alone for the Treatment of Colorectal Cancer

Status:
Completed

Trial end date:
2016-11-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to determine whether treatment with ZACTIMA (vandetanib) in combination with FOLFOX is more effective than FOLFOX alone for colorectal cancer in patients who have failed therapy with an irinotecan and fluoropyrimidine containing regimen.

Phase:

Phase 2

Details

Lead Sponsor:

Genzyme, a Sanofi Company

Treatments:

Fluorouracil
Folic Acid
Leucovorin
Levoleucovorin
Oxaliplatin